Clinical Trial Update: Safety and Efficacy of Melflufen and Dexamethasone in Relapsed and/or Relapsed-Refractory Multiple Myeloma Patients [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating melflufen plus dexamethasone in relapsed/refractory multiple myeloma; terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• And or Relapsed-refractory Multiple Myeloma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Melflufen (melphalan flufenamide)

Snippet

Sponsor: Oncopeptides AB | Conditions: Relapsed and/or Relapsed-refractory Multiple Myeloma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2020-08-24